

# A Study to Evaluate the Effect of Food and Proton Pump Inhibitor on the Pharmacokinetics of ZN-A-1041 in Healthy Participants

NCT07329972

---

Status	RECRUITING
Phase	Phase 1
Sponsor	Genentech, Inc.
Enrollment	48 participants

## Key Eligibility Criteria

---

### Inclusion (11)

- Body mass index (BMI) within the range of 18 to 32 kg/m<sup>2</sup>, inclusive
  - In good health, determined by no clinically significant findings from medical history, physical examination, 12-lead ECG, and vital signs, as determined by the investigator, at Screening and Check-in, as applicable
  - Clinical laboratory evaluations (including chemistry panel, CBC, and UA with complete microscopic analysis) within the normal reference ranges for the certified test laboratory at Screening and Check-in
  - Negative test for selected drugs of abuse at Screening and Check-in (includes alcohol)
  - Negative hepatitis panel (hepatitis B surface antigen, hepatitis B core antibody, hepatitis B surface antibody [unless consistent with vaccination or immunity due to natural infection], and hepatitis C virus antibody) and negative HIV antibody screens
- ... and 6 more (see full listing online)

### Exclusion (31)

- Significant history or clinical manifestation of any metabolic, allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal (GI), neurological, or psychiatric disorder, as determined by the investigator
  - History or concurrent clinically significant hemorrhagic, bleeding abnormalities, as determined by the investigator
  - Personal or family history of congenital long QT syndrome
  - History of significant hypersensitivity, intolerance, or allergy to any drug compound, food, or other substance, unless approved by the investigator
  - History of GI surgery or resection that would potentially alter absorption and/or excretion of orally administered drugs except that uncomplicated appendectomy and hernia repair will be allowed
- ... and 26 more (see full listing online)

## Locations (2 total)

---

Daytona Beach Clinical Rsch Unit, Daytona Beach, Florida, United States  
Fortrea Clinical Research Unit - Dallas, Dallas, Texas, United States